Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
I agree £15 is a reasonable target price. Strong balance sheet and current ratio should mean it survives any large market turbulence. The high sensitivity troponin test, should help drive future growth in 2017 onwards. Been some papers talking about it recently. To quote the last interm report "Revenues from this test (Troponin) could easily grow to dwarf the current business." http://www.bbc.co.uk/news/health-30896795 http://www.bmj.com/content/350/bmj.g7873.full.print?
Someone seems to building a big stake in Bioventix at the moment.
Companies house shows Pref shares have now been cancelled (stated in annual report). https://beta.companieshouse.gov.uk/company/03248123/filing-history The company now has £100,000,000 shares at 1p. Hopefully, LSE can update the fundamental information tab.
Another 50,000 Bought today (£129.88k). Someone is building their stake.
241,033 shares (£620.66k) bought the day before the interms. I wonder if that was Woodford or Invesco.
Jobbio, Maytech and Sagacity Solutions seem to be MXCP's potential candidates who do not yet have a AIM listing. I hope they choose Sagacity for the rev. acquisition personally. Seems to be the most interesting with rapid growth in revenue and EBITDA.
Hi Matt, Have you seen the current ratio for this stock. It has a lovely balance sheet, dividend cover. What is not to like. For some reason LSE is not giving financial info for this. Go to morningstar they give you 5 years worth.
Hi Matt, No price target. I am in this for the long term. I like its financial characteristics, business structure/royalty payments. It is like abcam but more reasonably priced. How about you? Why are you here.
I noticed you have sent a few messages of encouragement to Mr Dobbie on twitter :)
Profits are significantly ahead of market market expectations
Court order has gone through at last (28th Aug). (Reduction of share capital, cancellation of share premium account and cancellation of capital redemption reserve.) https://beta.companieshouse.gov.uk/company/SC368538/filing-history
The lack of interest is probably good at this stage. It allows a big discount to NAV to form. SARS can then use up there cash pile buying back the stock at a large discount. Hopefully getting rid of the large share overhang. They will no doubt try to promote the company abit more once the cash is used up.
No the share is not suspended.
It amazes me how it is possible to suppress the prices of these small companies. Still price is recovering. All the way to 920p at least.
What will move this share? All those shares bought and cancelled (15%) and still no price movement.
Thanks for the estimate Chomsky.
If it is 365Agile. A premium for CSI of 50% above cash value seems reasonable. I set my first target price at 44.25p. It should go higher once more info released. From memory, directors said the acquisition will be done by the end of December. Internet of things "IOT" is very hot at the moment.
Hi Chomsky, Others are speculating that Agile could be reversed into CSI. What value would you put on 365Agile ?
The dividend of £2,136,000 paid to shareholders in July 2014 was potentially unlawful because no financial statements demonstrating that the company had distributable profits were lodged with Companies House. At the date of approval of these financial statements a contingent asset relating to the potential recovery from shareholders of this dividend exists. The directors have no intention of seeking to recover the amounts involved and intend to resolve the issue by putting a deed of resolution to a general meeting absolving the directors of any fault and the shareholders from any claims for recovery of the dividend.
Hi the_shareminator, Good to see another poster. I think they will complete all of the buy back just in time for the annual report. Then they can use a improved EPS. I bet the 12.5M share sale was part of the buyback. All the other recent large sales were them.